Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Atomo Diagnostics Ltd. ( (AU:AT1) ) just unveiled an update.
Atomo Diagnostics Limited announced that it will release its Q4 FY25 results on July 29, 2025, followed by a results briefing webinar hosted by Managing Director & CEO John Kelly. This announcement highlights Atomo’s commitment to transparency and engagement with analysts and investors, potentially impacting its market positioning and stakeholder relations.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Limited is an Australian-headquartered medical device company that provides unique, integrated rapid diagnostic test devices to the global diagnostic market. The company focuses on simplifying testing procedures, enhancing usability, and improving reliability for rapid point-of-care and at-home testing applications. Atomo has commercialized several products internationally and has supply agreements for testing applications targeting infectious diseases such as COVID-19, HIV, viral vs bacterial differentiation, and female health.
Average Trading Volume: 951,476
Technical Sentiment Signal: Hold
Current Market Cap: A$14.97M
For detailed information about AT1 stock, go to TipRanks’ Stock Analysis page.